Validation Data Gallery
Tested Applications
Recommended dilution
| Application | Dilution |
|---|---|
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Product Information
87691-3-PBS targets CD27/TNFRSF7 in WB, Indirect ELISA applications and shows reactivity with rat samples.
| Tested Reactivity | rat |
| Host / Isotype | Rabbit / IgG |
| Class | Recombinant |
| Type | Antibody |
| Immunogen |
CatNo: Eg5288 Product name: Recombinant rat CD27/TNFRSF7 protein Source: mammalian cells-derived, V37 Tag: C-rFc Domain: 21-181 aa of NM_001024335.1 Sequence: TPAPNNCPDRHYWIGAGLCCQMCGPGTFLVKHCDQDRAAAQCDPCIPGTSFSPDYHTRPHCESCRHCNSGFLIRNCTVTANAECTCSKGWQCRDQECTECDPPLNPALTSQPSEAPSPQLPPPTHLPYATEKPSWPPQRQLPDSTVYSRLPSQRPLCSSDC 相同性解析による交差性が予測される生物種 |
| Full Name | CD27 molecule |
| Calculated molecular weight | 28 kDa |
| Observed molecular weight | 50 kDa |
| GenBank accession number | NM_001024335.1 |
| Gene Symbol | Cd27 |
| Gene ID (NCBI) | 500318 |
| Conjugate | Unconjugated |
| Form | |
| Form | Liquid |
| Purification Method | Protein A purification |
| UNIPROT ID | Q501W2 |
| Storage Buffer | PBS only{{ptg:BufferTemp}}7.3 |
| Storage Conditions | Store at -80°C. |
Background Information
Rat CD27 (TNFRSF7) is a member of the tumor necrosis factor receptor superfamily (TNFRSF). It is a type I transmembrane glycoprotein primarily expressed on the surface of T lymphocytes, B cells, and natural killer (NK) cells. As an important T cell co-stimulatory molecule, CD27 binds to its ligand, CD70. This interaction recruits TRAF2/5, activating the NF-κB and JNK signaling pathways, which promotes T cell proliferation, differentiation, and survival while inhibiting apoptosis. The expression level of CD27 serves as a crucial marker for T cell activation and memory status, and soluble CD27 (sCD27) can act as a clinical marker of immune activation. In cancer immunotherapy, CD27 is a significant target. Agonistic antibodies, such as Varlilumab, can enhance anti-tumor T cell responses and have entered clinical trials.